May 20th, 12:30 PM

Identification of GDF-6 blocking antibodies as anti-melanoma therapeutics

Ejemel Monir
University of Massachusetts Medical School

Danielle Wisheart
University of Massachusetts Medical School

Alec Gramann
University of Massachusetts Medical School

See next page for additional authors

Follow this and additional works at: https://escholarship.umassmed.edu/cts_retreat

Part of the Cancer Biology Commons, Immunoprophylaxis and Therapy Commons, Medical Immunology Commons, and the Neoplasms Commons

Monir, Ejemel; Wisheart, Danielle; Gramann, Alec; Venkatesan, Arvind; Klempner, Mark S.; Ceol, Craig J.; and Wang, Yang, "Identification of GDF-6 blocking antibodies as anti-melanoma therapeutics" (2016). UMass Center for Clinical and Translational Science Research Retreat. 15.
https://escholarship.umassmed.edu/cts_retreat/2016/posters/15
Presenter Information
Ejemel Monir, Danielle Wisheart, Alec Gramann, Arvind Venkatesan, Mark S. Klempner, Craig J. Ceol, and Yang Wang

Keywords
bone morphogenetic protein, GDF6, melanoma

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.

This poster abstract is available at eScholarship@UMMS: https://escholarship.umassmed.edu/cts_retreat/2016/posters/15
Identification of GDF-6 blocking antibodies as anti-melanoma therapeutics

Monir Ejemel¹, Danielle Wisheart¹, Alec Gramann², Arvind Venkatesan², Mark S. Klempner¹, Craig J. Ceol²#, Yang Wang¹#

¹MassBiologics, University of Massachusetts Medical School, Boston, Massachusetts, USA
²Program of Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA

#Co-corresponding authors and Co-PIs for NHMPP award

Through comparative oncogenomic studies and functional analyses, we have identified the bone morphogenetic protein (BMP) factor GDF6 as a new melanoma oncogene. The secreted, carboxy-terminal portion of GDF6 is the active form that binds to cell-surface receptors to initiate BMP signaling. Targeted antibodies directed against secreted proteins are a proven therapeutic modality in several diseases.

To develop therapeutic antibodies against the active form of GDF6, we generated a panel of monoclonal antibodies. Due to the high similarity of human and mouse GDF6 proteins, the C-terminal GDF6 protein was expressed as bacterial recombinant protein with fusion tags to enhance immunogenicity. The Expresso Screening System (Lucigen) was used to select fusion tags, and MBP and SlyD were chosen for optimal protein solubility and purification recovery. Ten CD1 mice were immunized with GDF6-MBP fusion protein and robust immune responses were observed in all animals after 5 immunizations. Animals were sacrificed for hybridoma fusion, and hybridoma clones were screened by ELISA using GDF6-SlyD fusion protein to select clones with specific binding activity to GDF6. Over 70 monoclonal antibodies were identified with strong reactivity to GDF6, and a subset has been shown to recognize the endogenous, secreted form of GDF6 via western blot. These antibodies will be screened for their activity to block GDF6 binding to melanoma cells and ability to inhibit downstream signaling using both in vitro assays and in vivo xenograft models.